In vitro and in vivo efficacy of miramistin against drug-resistant fungi.

In vitro and in vivo efficacy of miramistin against drug-resistant fungi.

J Med Microbiol. 2019 Jun 06;:

Authors: Osmanov A, Wise A, Denning DW

Abstract
INTRODUCTION: Miramistin is a topical antiseptic with broad antimicrobial activity that was developed in the Soviet Union during the Cold War.
AIM: To investigate the antifungal activity of miramistin against clinically relevant drug-resistant fungi.
METHODOLOGY: The in vitro activity of miramistin was determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Mammalian cell toxicity was tested using a McCoy cell line and topical and systemic tolerability, and in vivo efficacy was tested using Galleria mellonella models.
RESULTS: The minimal inhibitory concentration (MIC) range against fungi was 1.56-25 mg l-1 (GM 3.13 mg l-1 ). In the G. mellonella model, miramistin provided potent survival benefits for Candida albicans and Aspergillus fumigatus infection. Miramistin was tolerated by McCoy cell lines at concentrations up to 1000 mg l-1 and was systemically safe in G. mellonella at 2000 mg kg-1. Topical administration at 32 000 mg l-1 was well tolerated with no adverse effects.
CONCLUSION: These findings support further investigation of miramistin and suggest its possible use for treatment of superficial fungal infections.

PMID: 31169488 [PubMed – as supplied by publisher]

Source: Industry